Prevention Research Funding Report 2017: Investment Slows and Continues to Concentrate in a Few Funders!
A new report issued at this year's HIVR4P conference states that flat and/or reduced funding for HIV/AIDS and other global health issues threatens to roll back progress worldwide.
This fact sheet is about research to find preventive vaccines for use by HIV-negative people.
In the Era of Daily PrEP, Feds May Stop Research Funding Gels, Rings, and Douches for HIV Prevention
The effectiveness of pre-exposure prophylaxis has played a role in diverting U.S. funding from microbicide research.
What are microbicides, why do we need them, and what is the status of current microbicide research? This fact sheet answers those questions and more.
A new HIV vaccine candidate has shown over 50% effectiveness in preventing transmission of an HIV-like virus in monkeys, according to a recent animal study.
Matthew Rose was a participant in HVTN 505, the recently cancelled high-profile HIV vaccine study. Despite disappointment over its failure, he offers an optimistic point of view on what the study results mean for the future of vaccine research.
This year, six vaginal microbicides are expected to enter into Phase III clinical trials, recruiting thousands of women who will be testing the efficacy and safety of these products. In the form of creams, gels, lubes or suppositories, vaginal micr...